Login / Signup

Leveraging Modeling and Simulation to Enhance the Efficiency of Bioequivalence Approaches for Generic Drugs: Highlights from the 2023 Generic Drug Science and Research Initiatives Public Workshop.

Arindom PalFang WuRoss WalengaEleftheria TsakalozouKhondoker AlamYuqing GongLiang ZhaoLanyan Fang
Published in: The AAPS journal (2024)
The 2023 Generic Drug Science and Research Initiative Public Workshop organized by the U.S. Food and Drug Administration (FDA) discussed the research needs to improve and enhance bioequivalence (BE) approaches for generic drug development. FDA takes such research needs and panel discussions into account to develop its Generic Drug User Fee Amendments III (GDUFA III) Science and Research Initiatives specific to generics. During the five workshop sessions, presentations and panel discussions focused on identifying and addressing scientific gaps and research needs related to nitrosamine impurity issues, BE assessment for oral products, innovative BE approaches for long-acting injectable products, alternative BE approaches for orally inhaled products, and advanced BE methods for topical products. Specifically, this report highlights the discussions on how to improve BE assessment for developing generic drug products based on research priorities for leveraging quantitative methods and modeling, as well as artificial intelligence/machine learning (AI/ML).
Keyphrases
  • artificial intelligence
  • machine learning
  • public health
  • adverse drug
  • quality improvement
  • big data
  • healthcare
  • deep learning
  • mental health
  • drug administration
  • drug induced
  • emergency department
  • high resolution